Detection of p53 in Hodgkin's disease using the monoclonal antibody PAb248

Journal of Pathology

Volumn 178, Issue 2, 1996, Pages 170-172

  Doussis Anagnostopoulou, Ipatia ^a   Remadi, Sami ^a   Kaklamanis, Loukas ^b   Pezzella, Francesco ^c   Gatter, Kevin C ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Hodgkin's disease; Immunohistochemistry; p53; PAb248

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REED STERNBERG CELL;

ANTIBODIES, MONOCLONAL; HODGKIN DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTES; NEOPLASM PROTEINS; REED-STERNBERG CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030062342     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199602)178:2<170::AID-PATH448>3.0.CO;2-Z     Document Type: Article

References (23)

1. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation Cell 1989; 57: 1083-1093.
2. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 Nature 1991; 352: 345-347.
3. Harris A. Mutant p53 - the commonest genetic abnormality in human cancer? J Pathol 1990; 162: 5-6.
4. Villuendas R, Piris MA, Orradre JL, et al. p53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1991; 138: 235-241.
5. Pezzella F, Micklem K, Turley H, et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 1994; 47: 592-596.
6. Hockenberry D, Nunez G, Milliman C, Screiber RD, Korsmeyer SJ. bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death Nature 1990, 348: 334-336.
7. Doussis IA, Pezzella F, Lane DP, Gatter KC, Mason DY. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin's disease. Am J Clin Pathol 1993, 99: 663-667
8. Yewdell JW, Gannon JV, Lane DP. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol 1986; 59: 444-452.
9. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes) J Histochem Cytochem 1984; 32: 219-229
10. Banks L, Matlashewski G, Crawford L. Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression Eur J Biochem 1986, 159: 529-534.
11. Gannon JV Jr, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect a monoclonal antibody specific for the mutant form. EMBO J 1990, 9: 1595-1602.
12. Van Veldhuizen PJ, Sadasivian R, Garcia F, et al. Mutant p53 expression in prostate carcinoma. Prostate 1993; 22: 23-30.
13. Gitsch G, Kainz C, Joura E, et al Mutant p53 product in patients with stage III cervical cancer Anticancer Res 1992, 12: 2241-2242
14. Kennedy SM, Macgeogh C, Jaffe R, et al. Overexpression of the onco-protein p53 in primary hepatic tumors of childhood does not correlate with gene mutations Hum Pathol 1994; 25: 438-442.
15. Effert PJ, McCoy RH, Walther PJ, et al. p53 gene alterations in human prostate carcinoma J Urol 1993; 150: 257-261.
16. Fujita M, Inoue M, Tanizawa O, et al. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection Cancer Res 1992; 52: 5323-5328
17. Scarpa A, Capelli P, Mukai K, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-1543.
18. Wynford-Thomas D p53 in tumour pathology: can we trust immunocyto-chemistry? J Pathol 1992; 166: 329-330.
19. Battifora H. p53 immunohistochemistry, a word of caution Hum Pathol 1994, 25: 435-436
20. Gupta R, Norton A, Thompson I, Lister T, Bodmer J. p53 expression in Reed-Sternberg cells of Hodgkin's disease Br J Cancer 1992; 66: 649-652
21. Doglioni C, Pelosio P, Mombello A, Scarpa A, Chilosi M. Immunohisto-chemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas Hematol Pathol 1991; 5: 67-73.
22. Iggo R, Gatter KC, Bartek J, Lane D, Harris AL increased expression of mutant forms of p53 oncogenes in primary lung cancer. Lancer 1990; 335: 675-677
23. Doussis-Anagnostopoulou I, Garrido M, Heryet A, et al. Proliferation in Hodgkin's disease: a study using three fixation-resistant markers Diagn Oncol 1993; 3: 302-306.